Lonza Group AG against Moderna, Inc. — live side-by-side technical comparison.
Prices as of 2026-09-23T15:30:29+00:00 UTC · updates daily
MRNA leads 4 of the 5 windows we measure — over 1 month LONN.SW is -4.4% and MRNA +31.1%; over year to date LONN.SW is +4.5% and MRNA +517.5%.
| LONN.SW | MRNA | |
|---|---|---|
| Price | $561.80 | $182.11 |
| 1 day | -0.2%lead | -0.2% |
| 5 days | +4.3% | +25.1%lead |
| 1 month | -4.4% | +31.1%lead |
| 6 months | +20.2% | +255.1%lead |
| Year to date | +4.5% | +517.5%lead |
| 52-week position | 75% of range | 94% of range |
| 52-week range | $454.60–$597.80 | $22.28–$192.31 |
| vs 50-day average | below $564.23 | above $104.86 |
| vs 200-day average | above $530.05 | above $62.57 |
| RSI (14) | 38 | 70 |
| Next earnings | 2026-01-28 | 2026-11-05 |
LONN.SW trades at $561.80, below its 50-day average of $564.23, and above the 200-day at $530.05. It sits at 75% of its 52-week range ($454.60–$597.80); 14-day RSI is 38, in neutral territory; an average session moves it about 1.9%. For levels, the first level overhead is $564.23 (0.4% away) and the first support below is $554.70 (1.3% down). On the checklist the page runs for every asset, 4 of 6 checks read bullish — the lean is bullish.
MRNA trades at $182.11, above its 50-day average of $104.86, and above the 200-day at $62.57. It sits at 94% of its 52-week range ($22.28–$192.31); 14-day RSI is 70, in overbought territory; an average session moves it about 6.3%. For levels, the first level overhead is $182.56 (0.2% away) and the first support below is $175.00 (3.9% down). On the checklist the page runs for every asset, 6 of 6 checks read bullish — the lean is bullish.
MRNA is the more volatile of the two — an average session moves it 6.3% against 1.9% for LONN.SW, so an identical position size carries roughly 3.3× the daily risk.
The comparison turns on those levels: LONN.SW clearing $564.23 or losing $554.70; MRNA clearing $182.56 or losing $175.00. Until one of them gives way, the relative reading above stands.